Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Imidafenacin in OAB
NCT00512785Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of imidafenacin in overactive bladder (OAB) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Adverse Events at 64 weeks, Laboratory Tests at 64 weeks and 3 more. Started Aug 2007; status: completed.
02
Drugs
imidafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00512785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00512785.